Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 15/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699619 | 0.92 | MDM2 (0.42) | MDM2MEN1KMT2AIDEATM | |
| SCHEMBL13699621 | 0.87 | MDM2 (0.37) | MDM2MEN1KMT2AATM | |
| SCHEMBL4168260 | 0.81 | MDM2 (0.48) | MDM2CNR1MEN1KMT2AIDE | |
| SCHEMBL4168266 | 0.81 | MDM2 (0.48) | MDM2CNR1MEN1KMT2AIDE | |
| SCHEMBL13699614 | 0.79 | MDM2 (0.43) | MDM2CNR1MEN1KMT2AIDE | |
| SCHEMBL13699612 | 0.78 | MDM2 (0.42) | MDM2CNR1MEN1KMT2ALMNA | |
| SCHEMBL13699613 | 0.77 | MDM2 (0.41) | MDM2CNR1LMNAMAPK1 | |
| SCHEMBL11958529 | 0.76 | MDM2 (0.51) | MDM2CNR1 | |
| SCHEMBL11979587 | 0.76 | MDM2 (0.51) | MDM2CNR1 | |
| SCHEMBL13699571 | 0.76 | MDM2 (0.46) | MDM2MEN1KMT2AIDE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885CNR1 2/4885MEN1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.